CELL INTELLIGENCE · 肿瘤细胞治疗研究

PARP 抑制剂奥拉帕利增强大剂量化疗与自体干细胞移植治疗难治性淋巴瘤

Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma.

在这项首次将 PARP 抑制剂与 HDC 联合的试验中，olaparib/vorinostat/GemBuMel 是安全的，并在难治性淋巴瘤中显示出有前景的活性，包括 CAR-T 治疗后复发者。

结节性淋巴细胞为主型霍奇金淋巴瘤：疾病生物学、风险分层和治疗进展

Nodular lymphocyte-predominant Hodgkin lymphoma: advances in disease biology, risk stratification, and treatment.

淋巴瘤的 CAR-T 细胞治疗：新场景与未来方向

Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions.

经典型霍奇金淋巴瘤的 CAR-T 细胞治疗

CAR-T Cell Therapy for Classical Hodgkin Lymphoma.

血液系统恶性肿瘤成人接种 SARS-CoV-2 疫苗后的抗体反应：系统综述和 meta 分析

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.

血液系统恶性肿瘤成人接种 SARS-CoV-2 疫苗后的抗体反应：系统综述和 meta 分析

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.

儿童和青少年癌症患者 CAR-T 细胞药物研发儿科战略论坛：ACCELERATE 与欧洲药品管理局合作、美国食品药品监督管理局参与

Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE i